EM
Therapeutic Areas
Novartis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Fabhalta® (iptacopan) | Immunoglobulin A Nephropathy (IgAN) | Approved / Phase III |
| Anti-IgE program (Excellergy) | Allergic Diseases | Pre-clinical |
| Pluvicto® | Prostate Cancer | Approved / Lifecycle |
| Lutathera® | Neuroendocrine Tumors | Approved / Phase III |
| Kisqali® (ribociclib) | HR+/HER2- Breast Cancer | Approved / Lifecycle |
| Leqvio® (inclisiran) | Hypercholesterolemia | Approved |
| Scemblix® (asciminib) | Chronic Myeloid Leukemia (CML) | Approved / Lifecycle |
| Iptacopan (LNP023) | C3 Glomerulopathy (C3G) | Phase III |
Leadership Team at Novartis
GC
Giovanni Caforio, M.D.
Board Chair
SM
Simon Moroney, D.Phil.
Board Vice-Chair
NC
Nancy C. Andrews, M.D., Ph.D.
Board Member
PB
Patrice Bula
Lead Independent Director
CS
Charles Swanton, M.B.Ph.D.
Board Member
JD
John D. Young
Board Member
BH
Bridgette Heller
Board Member
TB
Ton Buechner
Board Member
E(
Elizabeth (Liz) Doherty
Board Member
FV
Frans van Houten
Board Member